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1. Introduction 
NAFLD is associated with major cardiovascular risk factors including type 2 diabetes 
mellitus (T2DM), obesity, dyslipidemia, hypertension and insulin resistance and constitutes 
a new component of the metabolic syndrome (MetS) [1-2].The association of MetS and 
NAFLD is so strong that NAFLD is considered as the hepatic manifestation of MetS [3]. The 
clinical implication of NAFLD and nonalcoholic steatohepatitis (NASH) are mainly derived 
from their common occurrence in the general population (15%-30%) and their potential to 
contribute to CAD, extra hepatic cancer, diabetes, and progression to fibrosis (30%-40%), 
cirrhosis (20%-30%) and hepatocellular carcinoma [4-5]. Although the mechanisms 
underlying liver disease progression remain unclear, insulin resistance and obesity-related 
inflammation, obesity related ectopic fat and lipotoxicity play a key role, along with possible 
genetic, dietary and life style factors [6].  
Most studies show that MetS is associated with a two-fold increase in CAD risk and a 5-fold 
increased risk for incidences of T2DM [7-12]. The importance of NAFLD component within 
the MetS is now increasingly recognized, and this has stimulated an interest in the possible 
relationship between NAFLD and cardiovascular disease (CVD). This review focuses on the 
relationship between NAFLD and CAD, the Biological mechanisms linking NAFLD and 
CAD and a proposed new treatment approach for patients with NAFLD.  
2. The relationship between NAFLD and CAD  
Prevalence:  NAFLD affects 15-30% of the general population [13]. The prevalence is also 
high in overweight and obese children [14]. Factors contributing to NAFLD include 
sedentary life style, and increased consumption of foods with high fat and high fructose 
corn syrup content (soft drinks). Steatosis is associated with an increased prevalence and 
incidence of CAD and cardiovascular mortality. [15- 16]. 
Clinical studies: Targher et al showed a significant increase of carotid intima-media 
thickness (IMT) in the presence of NAFLD [17]. Brea et al showed that patients with NAFLD 
had increased intima-media thickness (IMT), independently by the MetS [18]. Lin et al 
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showed that patients with NAFLD were more likely to have CAD compared to patients 
without NAFLD, independent of obesity and other risk factors [19]. Villanova et al showed 
that NAFLD patients have a significant decrease in brachial artery flow- mediated 
vasodilatation, which correlates with the extent of liver disease. Furthermore, the 10-year 
probability of coronary heart disease (as calculated according to the Framingham risk score) 
was moderately increased in NAFLD patients, and particularly in patients with NASH [20]. 
This study and others provide evidence of severe endothelial dysfunction and increased risk 
of cardiovascular events in NAFLD [21]. Targher et al showed an increased prevalence of 
CAD in patients with T2DM and NAFLD as compared with diabetic patients without 
NAFLD [22] and that the severity of liver histology among NAFLD patients is strongly 
associated with early carotid atherosclerosis, independent of classical risk factors, insulin 
resistance, and the presence of MetS [23]. Akabame et al showed that NAFLD is a novel risk 
factor for vulnerable plaques, using a multislice computed tomography (MSCT) [24]. Recently, 
we showed that patients with NAFLD, even without MetS, have more vulnerable coronary 
soft plaques than healthy controls. [25] (Figure 1). Pacifico et al demonstrated that obese 
children with NAFLD have a marked increase in carotid IMT in comparison with control 
healthy children, and that the carotid IMT was higher for obese children with NAFLD than 




Fig. 1. Presence of coronary plaque in patients with Non Alcoholic Fatty Liver Disease 
3. Cause of death in patients with NAFLD  
The mortality rate among patients with NAFLD followed for 8 years was higher than in the 
general population, [27]. In another study consisting of biopsy-proven, NAFLD patients 
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who were followed for 18 years, CVD was among the common causes of death after all of 
the cancers combined [28]. In the Valpolicella Heart Diabetes Study, Targher et al showed 
that NAFLD patients have been associated with an increased incidence of major CVD events 
after excluding classical risk factors, diabetes duration, glycemic control, medication use, 
and components of the metabolic syndrome [29-30]. Dunn et al showed that NAFLD 
patients had significantly increased all-cause mortality and cardiovascular mortality, 
especially in the 45-54 years age group [31].  A strong association between mildly elevated 
serum liver enzymes as a surrogate marker of NAFLD and increased risk for CVD mortality 
and morbidity was reported in several population-based cohort studies [21, 32, 33]. A 
Swedish study consisting of 129 patients with NAFLD showed that patients with NASH had 
higher incidences of cardiovascular mortality compared to the reference population [34]. 
Recently, other studies with 28 years follow up showed that CAD was the leading cause of 
death in patients with NAFLD, followed by hepatic and extra hepatic malignancy and 
finally by cirrhosis and its complications  [35, 36, Table 1]. 
 
% Number of patients Cause of death 
35.0 15 CAD 
28.0 12 Extra hepatic cancer 
18.6 8 Liver cancer, cirrhosis 
7.0 3 Diabetes mellitus 
6.8 3 Poisoning 
2.3 1 Intestinal Perforation   
2.3 1 Alcohol abuse 
Table 1. Causes of Death in 143 patients with NAFLD (death= 43) 
4. Classical and emerging risk factors for atherosclerosis  
The new risk factors for CAD include markers for inflammation (e.g. CRP, lipoprotein A), 
homocystine, markers of fibrinolytic and homeostatic function (e.g. fibrinogen, tissue 
plasminogen activator, and plasminogen activator inhibitor-1). These markers are also 
associated with NAFLD [37-41]. The classic common risk factors for NAFLD and CAD are 
age and gender [42, 43], physical inactivity [44- 47], T2 DM [48-52], hyperlipidemia [53- 56], 
obesity [57-63], and hypertension [64- 66]. These risk factors are well known and beyond the 
scope of this review. 
5. Mechanisms linking NAFLD and CAD 
The biological mechanisms potentially responsible for accelerated atherogenesis in NAFLD 
patients may either have origin in the liver or have the liver as the target of systemic 
abnormalities. Here we will discuss the biological mechanisms linking NAFLD and CAD, 
the novel risk factors for CAD, and the common pathways of both diseases (Figure 2) 
A) Oxidative stress 
Oxidative stress plays an important role in the progression from simple steatosis to 








Fig. 2. Biological mechanism of accelerated atherosclerosis in patients with NAFLD. Fat 
accumulation in the liver induces hyperglycemia, sub clinical inflammation, atherogenic 
dylipidemia, lipotoxicity, and the secretion of cytokines. Thereby inducing insulin 
resistance, atherosclerosis, and diabetes mellitus. All  contributes to coronary artery 
diseases.  
NASH which show either increased reactive oxygen species (ROS) formation or evidence of 
extensive lipid peroxidation [68,69]. The association between oxidative stress and NAFLD in 
humans is supported by the immunohistochemical detection of lipid peroxidation products 
and 8-hydroxy-deoxyguanosine in the plasma and liver biopsies from patients with NAFLD 
[70, 71]. The earliest events in the pathogenesis of atherosclerosis are thought to be changes 
in endothelial functions, in turn triggered by oxidative modification of low-density 
lipoproteins (LDL), leading to the formation of oxidized LDL in the subintimal space [72 ]. 
The expression of chemotactic factors such as monocyte chemotactic protein-1 
(MCP-1) is enhanced by oxidative stress and oxidized LDL Endothelial expression of 
vascular cell adhesion molecule-1 (VCAM-1), which is regulated through a redox-sensitive 
mechanism, promotes the adhesion of monocytes to the endothelium. The release of 
macrophage colony-stimulating factor (M-CSF) is also stimulated by modified LDL. 
Expression of these factors results in the attraction and adhesion of monocytes to the arterial 
wall and the promotion of their differentiation into tissue macrophages. Exposure to the 
superoxide ion, a ROS, activates the nuclear factor kappa-B (NF-kappa B) regulatory 
complex and triggers the transcription of several atherosclerosis-related genes (VCAM-1, 
MCP-1, tumor necrosis factor (TNF), matrix metalloproteinase (MMP)-9 and procoagulant 
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tissue factor). This series of events leads to the accumulation of macrophages in the arterial 
wall, which then avidly incorporate oxidized LDL to form foam cells. Oxidized LDL, in 
turn, stimulates the release of interleukin-1 from macrophages. The activity of MMPs is also 
regulated by oxidative stress and appears to be closely linked to smooth muscle cell 
activation and migration. MMPs have also been implicated in the physiopathology of 
plaque rupture. Furthermore, ROS can lead to platelet activation and thrombus formation.  
Therefore, oxidative stress appears to be important in both the early and later stages of the 
atherosclerotic process [73, 74]. 
B) Insulin resistance 
NAFLD is strongly associated with hepatic and adipose tissue insulin resistance (IR), as well 
as reduced whole-body insulin sensitivity [75]. Previous studies have documented a 
reduction of 45-50% in glucose disposal, and an impaired ability of insulin to suppress 
endogenous glucose production (hepatic IR) in subjects with NAFLD [76]. The spectrum of 
metabolic disturbances associated with IR extends beyond hyperglycemia and includes 
dyslipidemia, obesity, hypercoagulability, and inflammation. In long-term follow-up of 
patients with T2DM, IR was independently predictive of CAD, with a 1-unit increase in IR 
assessed by the homeostasis model assessment (HOMA) associated with a 5.4% increased 
risk for CAD [77]. Increased levels of fatty acids, (NEFA), lipotoxicity and disturbances in 
adipokine secretion, are believed to be related to insulin resistance. Increased levels of 
NEFA might affect the endothelial nitric oxide production, thereby impairing endothelium-
dependent vasodilatation. They may increase myocardial oxygen requirements and, 
therefore. ischemia. Recent evidence in older men with CAD has shown that NEFAs are 
independently associated with cardiovascular mortality [78]. The Insulin Resistance and 
Atherosclerosis Study (IRAS) also confirmed the relation between IR and atherosclerosis in 
the carotid artery [79]. Overall, growing evidence suggests that hepatic insulin resistance is 
sufficient to induce several components of the metabolic syndrome and promote 
progression to cardiovascular disease 
C) Sub clinical inflammation 
Targher et al showed that in healthy non-smoking volunteers, plasma CRP, fibrinogen, von 
Willebrand factor (v-WF) and plasminogen activator inhibitor-1 (PAI-1) activity levels were 
markedly higher in subjects with hepatic steatosis than in those without, even after 
controlling for other confounders such as age, BMI, blood pressure, insulin resistance and 
triglyceride levels [80]. Recently, Il-6 and CRP have been shown to correlate with higher 
degrees of fibrosis and inflammation (i.e. NASH) in patients with NAFLD [81]. Thus, 
NAFLD/NASH should be considered a chronic inflammatory condition. Recent advances in 
basic science have established a fundamental role for inflammation in mediating all stages of 
atherosclerosis from initiation through progression and, ultimately, the thrombotic 
complications of atherosclerosis.  
Prospective epidemiological studies have found increased vascular risk in association with 
increased inflammatory markers such as, IL-6, TNF-α, CRP and fibrinogen [82-85]. Elevated 
values of circulating inflammatory markers commonly accompany acute coronary 
syndrome (ACS). Such elevations correlate with in-hospital and short-term prognosis [85, 
86].Chronic subclinical inflammation is a common finding in NAFLD and in atherosclerosis. 
Moreover, chronic sub clinical inflammation is strongly involved in IR and MetS, as mainly 
demonstrated by mechanistic studies in animal models [87]. Ectopic fat deposition in 
visceral adipose depots, heart and other depots increases the expression of visceral 
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proinflammatory mediators such as monocyte chemotactic protein-1 and IL-6, leading to 
local macrophage infiltration and associated systemic chronic inflammation [88].  
Hepatic steatosis is associated with increased production of pro-inflammatory cytokines by 
hepatocytes and non-parenchymal cells, including Kupffer cells and hepatic stellate cells. 
Increased intra-hepatic cytokine expression results from local NF-kB activation, mediated by 
hepatocellular damage and fat-derived factors, and is likely to play a major role in NAFLD 
progression and CVD pathogenesis [81, 88-90]. 
An atherogenic role of liver inflammation is supported by the observation that CAD risk is 
greater in NASH than in simple hepatic steatosis [27, 28].  
D) Adiponectin 
Liver fat accumulation, NEFAs, adiponectin, low-grade inflammation in the context of 
insulin resistance patient with fatty liver, might explain the development of endothelial 
dysfunction and early cardiovascular disease. Mature adipocytes act as an active endocrine 
and paracrine organ, secreting an increasing number of growth factors that participate in 
diverse metabolic processes, particularly IR. Patients with NAFLD exhibit reduced levels of 
adiponectin, which are inversely correlated with the severity of NAFLD histology [91-93]. 
The reduced production of adiponectin associated with obesity may contribute to the 
progression of NAFLD [89]. Adiponectin increases the expression of messenger RNA and 
protein production of tissue inhibitor of metalloproteinase in macrophages through the 
induction of IL-10 synthesis and selectively suppresses endothelial cell apoptosis [94, 95]. 
This suggests that adiponectin protects plaque rupture by the inhibition of matrix 
metalloproteinase function. Endothelium-dependent vasoreactivity is impaired in people 
with hypoadiponectinaemia, which might be at least one cause of hypertension in visceral 
obesity [96]. The protein inhibits the expression of adhesion molecules, such as vascular cell 
adhesion molecule-1 (VCAM-1), ICAM-1 and E-selectin, through the inhibition of NF-ĸB 
activation; it also suppresses foam-cell formation. From this, it is clear that adipokines are 
capable of contributing to remodeling of the myocardial extracellulat matrix [96]  
E) Myocardial Lipotoxicity 
Increasing plasma free fatty acids for few hours causes endothelial dysfunction and induces 
the production of systemic inflammation, and pro coagulants in vitro, in animal models and in 
humans. Of interest, free fatty acid impairs nitric oxide production by endothelial cells through 
the activation of an IKKb- mediated response. For instance, subjects with either glucose 
intolerance or T2DM have a significant increase in myocardial triglyceride content. There is a 
significant correlation between the development of fatty liver and abnormalities in left 
ventricular energy metabolism.  [97]. In Diabetic patients with NAFLD, fatty liver and elevated 
aminotransferases coexist with myocardial insulin resistance and coronary dysfunction [97]  
F) Atherogenic dyslipidemia 
Liver fat accumulation originate from peripheral fats stored in adipose tissue that flow to 
the liver via the plasma nonesterified fatty acid (NEFA, 60%) pool, fatty acids newly made 
within the liver through de novo lipogenesis (DNL, 30%), and from dietary fatty acid uptake 
(10%). The fat of lipids entering the liver may be secreted as very low-density lipoprotein 
(VLDL) triglycerides, oxidized or stored. The major component of dyslipidemia in NAFLD 
patients is an elevation of serum triglycerides (TG) which comes mainly from increased 
concentration of VLDL. In addition to increased synthesis of VLDL, there is also decreased 
clearance of triacylglycerol-rich lipoprotein (TRLs) induced by a decrease in lipoprotein 
lipase activity [98]. Other components of dyslipidemia, such as formation of small dens low-
density lipoprotein (LDL), are closely associated with IR and hypertriglyceridemia [99]. 
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VLDL1 triglyceride is a major predictor of LDL size. It seems that stimulated hepatic lipase 
activity favors the formation of small dense LDL particles. The increased activity of hepatic 
lipase in IR conditions such as in NAFLD and obesity produces smaller HDL particles, 
leading to increased HDL elimination [100]. In addition, increased levels of VLDL1 alter the 
composition of HDL, leading finally to an increased catabolism of these particles, which 
explains the inverse correlation of HDL and liver fat [101]. In summary, patients with 
NAFLD have increased levels of VLDL, TG, and small dense LDL particles and decreased 
levels of HDL. The presence of small dense LDL particles is associated with increased CVD 
risk [102]. Small dense LDL particles can move through endothelial fenestrations, entering 
the subendothelial space where inflammation and transformation into plaque can occur, and 
leading finally to coronary artery diseases [103]. Further, alterations in smooth muscle ion 
channels, Ca2+ handling, and cell signaling may be important mechanisms leading to 
coronary micro vascular dysfunction [103].  
G) Postprandial lipemia 
Exaggerated postprandial lipemia is an established CVD risk in T2DM [104]. Studies 
comparing the postprandial response of TG and FFA to a fat rich meal in nondiabetic 
subjects with biopsy proven NASH to control subjects showed that patients with NASH had 
significantly higher postprandial TG levels than healthy control subjects [105]. Other studies 
support a close relationship between dietary habits, postprandial lipemia and CAD [106]. 
The atherosclerotic risk of postprandial hyperlipidemia is derived from an increase of 
remnant lipoproteins (RLPs) [107]. In patients with IR, an increase of postprandial RLP 
values usually occurs and becomes a coronary risk factor. The RLP is easily taken into the 
macrophage in the arterial wall via the apolipoprotein B48 receptor, promoting foam cell 
formation of macrophages and performing the atherosclerotic lesion as is oxidized LDL 
[108]. Stanhope et al showed that consumption of fructose-sweetened but not glucose-
sweetened beverages for 10 weeks increases de novo lipid synthesis and the 24-hour 
postprandial TG including increased levels of apoB, LDL, oxidized LDL, RLP triglyceride, 
and the apoB / apoA1 ratio ( all biomarkers of increased for CAD) [109]. 
Dietary habits and genetic determinants, including microsomal transfer protein (MTP) 
polymorphisms, may promote NASH and atherogenesis via hypoadiponectinaemia 
[110,111]. Recently, Musso et al reported that the risk of adiponectin single-nucleotide 
polymorphisms (SNPs) 45TT and 276 GT are significantly more prevalent in NAFLD than in 
the general population and are associated with the severity of liver disease. In addition, an 
association with an atherogenic postprandial lipoprotein profile in NASH was detected 
independently of fasting adipokine and lipid levels [112]. 
H) Pro-coagulation and hypofibrinolysis 
The prothrombotic state in the atherosclerosis process encompasses platelets 
hyperaggregability, hypercoagulability and hyperfibrinolysis. Markers of fibrinolytic and 
hemostatic function (e.g. fibrinogen, tissue plasminogen activator, and plasminogen 
activator inhibitor 1-antigens), are strongly associated with NAFLD.  Plasminogen 
activator inhibitor-1(PAI-1) is expressed in visceral adipose tissue. It is mainly expressed 
in stromal cells including monocytes, smooth muscle cells and pre-adipocytes [113]. 
Plasma PAI-1 levels are  more closely related to fat accumulation and PAI-1 expression in 
the liver than in adipose tissue, suggesting that, among insulin-resistant individuals, the 
fatty liver is an important site of PAI-1 production [114]. We showed also that there is an 
association between the thrombotic risk factors and the extent of fibrosis in patients with 
NAFLD [40]. This confirms the central role of the liver in these processes. Fibrinogen, von 
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Willebrand factor (vWF) and PAI-1 are also considered markers of the acute-phase 
reaction of inflammation and thrombosis, and has been closely linked to CAD and 
diabetes mellitus [115]. CRP increases PAI-1 expression and activity in human aortic 
endothelial cells [116].  
6. Clinical implications 
It is evident that patients with NASH are more prone to develop CAD (Increase mortality by 
86%) than patients with simple steatosis (increase mortality by 55%, 117); however, it has 
not been clear until now whether the treatment of NAFLD patients will prevent CAD 
development. We suggest adding a new modality of approaching patients with NAFLD. 
Once the diagnosis of NAFLD was made, the first step will be a lifestyle intervention using a 
combination of diet, active walking, and behavior modification [118], with a goal of >10% 
weight reduction [119]. Mediterranean diet derived mainly from olive oil (rich in omega-9) 
is recommended [120,121]. We advise to reduce or discontinue the consumption of fast 
foods and regular soft drinks, which contain fructose [122]. Recently Dunn et al showed that 
modest wine drinking (20-30 gram/daily) offers protection against suspected NAFLD 
[123].The second step is to assess the risk of hepatic fibrosis: There are two modalities of 
assessment of fibrosis in NAFLD: The noninvasive methods of fibrosis include BARD score 
or Angulo score [124,125]. The invasive methods (liver biopsy) remains the only reliable 
means to determine prognosis based on the severity of fibrosis. 
The third step will include the assessment of cardiovascular risk stratification: We suggest 
the use of the Framingham score with effort test and/or measurements of the carotids 
arteries (IMT) as well as biomarkers of inflammation (CRP, fibrinogen), oxidative stress, 
(MDA, Paraoxonase), Insulin Resistance, (HOMA), lipotoxicity (TG, HDL, LDL, TC), OGTT, 
and microalbumin/creatinin ratio [126].  
The fourth step includes the assessment of malignancy: For patients older than > 45. 
Colonoscopy, mammography, chest X-ray, gynecology consultation, and tumor markers 
(CEA, AFP, PSA, and CA19-9, and CA125, stool blood) are recommended since malignancy 
is the second most common cause of death in patients with NAFLD [127]. The final step is to 
initiate an appropriate therapy according to the comorbidities, and the clinical status of each 
patient. A combination therapy is favored.  
A) Patients with metabolic syndrome 
The most effective antidiabetic agent is metformin especially in obese T2DM or pioglitazone 
in non-obese patients [128,129]. We advice to delay early insulin therapy because it may 
increase fibrosis and weight [130]. Whether insulin increases the risk of HCC or not is still 
under debate. Exenatide induces significant weight loss, which may lead to an insulin-
sensitizing effect [131]. Gliptins are a group of drugs, which increase incretin levels by 
inhibiting the enzyme DPP-4. These agents are relatively new and, as for the GLP-1 
analogues, improve insulin resistance in prediabetic individuals and patients with T2DM 
after weight loss [132]. Lipid-lower agents are mandatory treatment in diabetic patients with 
NAFLD, statins and fibrates for dyslipidemic and diabetic patients [133-135] are 
recommended. Renin-angiotensin system (RAS) inhibitors or alpha-blockers for 
hypertensive patients [136,137]. However, these types of medicines are not approved solely 
for fatty liver. Low dose aspirin is reasonable for patients with 10 years cardiovascular 
disease risk >10% and no risk factors for bleeding.  
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B) Patients without metabolic syndrome 
Best evidence for metformin or pioglitazone for 1-2 year in treating NAFLD patients without 
MetS. However, routine prescription of this drug (pioglitazone) needs further clarification. 
Vitamin E (400 IU/day) and omega-3 may be recommended [138,139]. However, vitamin E 
is not approved yet and high dosage may increase all cause mortality (140). Ursodeoxycholic 
acid has no benefit for NASH patients as compared to placebo (141). Statins for dyslipidemic 
patients. Aspirin to prevent CAD according to Framingham score (142).  Diagnosis of 
NAFLD may be a clear indication for diabetes screening, and cardiovascular risk screening 
and should be performed with the use of existing risk calculators and should be guided by 
established cardiovascular risk factors. 
 
a. For patients with metabolic syndrome: tailored therapy 
- Metformin/ Pioglitazon/Insulin for T2DM.  
- However, routine prescription needs further clarification 
- Statins /Fibrates for atherogenic dyslipidemia 
- Renin angiontensin system inhibitors/ α- blockers for hypertension 
b. For patients without metabolic syndrome: 
- Best evidence for metformin/ pioglitazone or vitamin E.  
- However, high dose vitamin E (>400 IU/day) may increase mortality 
- Currently, high dose ursodeoxycholic acid has no benefit for NASH patients 
- Omega-3 and vitamin D (2000 IU/day) may be beneficial.  
c. For the future: 
- Promising agents awaiting randomized controlled trials (Fatostatin, 
- (Aramchol, DPP-4 inhibitors, GLP-1 agonists and combination therapy) 
Table 2. Pharmacologic treatment of patients with NAFLD 
7. Conclusion 
NAFLD is a growing public health problem worldwide. The clinical impact of NAFLD on 
CAD risk deserves particular attention in view of the implications for screening and 
surveillance strategies in the growing number of NAFLD patients. NAFLD is associated 
with increased biomarkers level of chronic inflammation and atherosclerosis. 
Pharmacotherapy should be given for patients at high risk for complications (NASH, T2DM, 
obesity, atherogenic dyslipidemia). However, it is not currently known whether improving 
NAFLD will prevent the development and progression of CAD. Moreover, the prognostic 
value of NAFLD in CAD risk stratification has yet to be determined. NAFLD patients 
should be candidate not only for aggressive treatment of their liver disease , but also for 
aggressive treatment of underlying CAD risk factors, because many patients with NAFLD 
will have major CAD events and die prior to the development of advanced liver disease.  
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